COMMUNIQUÉS West-GlobeNewswire

-
MDxHealth Announces First Half 2017 Financial Results
31/08/2017 -
MDxHealth publie ses résultats financiers pour le premier semestre 2017
31/08/2017 -
Vistin Pharma ASA : Second quarter 2017 results - continuing strong demand for metformin
31/08/2017 -
VALNEVA : Résultats financiers solides & Progrès R&D majeurs au S1 2017
31/08/2017 -
VALNEVA: Reports Robust H1 2017 Financial Results & Major R&D Progress
31/08/2017 -
Santhera Announces Approval of Raxone® for LHON in Israel
31/08/2017 -
Bone Therapeutics announces H1 results for 2017
31/08/2017 -
Bone Therapeutics publie ses résultats du premier semestre 2017
31/08/2017 -
Bone Therapeutics appoints Jean-Luc Vandebroek as Chief Financial Officer
31/08/2017 -
Bone Therapeutics nomme Jean-Luc Vandebroek au poste de Directeur financier
31/08/2017 -
Merus participera à deux conférences Investisseurs en septembre 2017
30/08/2017 -
Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice
30/08/2017 -
ObsEva SA to Attend Baird Global Healthcare Conference and Rodman & Renshaw Annual Global Investment Conference in NYC
30/08/2017 -
Merus to Participate in Two Investor Conferences in September 2017
30/08/2017 -
Amer Sports updates its 2020 growth target, prioritizing Sustainable Profitable Growth
30/08/2017 -
Optalysys and The Earlham Institute Demonstrate Results of Breakthrough Optical Processing for Sequence Alignment
30/08/2017 -
Nicox réaffirme son éligibilité au PEA-PME
30/08/2017 -
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
30/08/2017 -
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
30/08/2017
Pages